ANGIODYNAMICS Percutaneous Introducer Set under the following labels: 1) 4 F Stiffened Micro-Intr...
FDA Device Recall #Z-0773-2017 — Class III — September 28, 2016
Recall Summary
| Recall Number | Z-0773-2017 |
| Classification | Class III — Low risk |
| Date Initiated | September 28, 2016 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Angiodynamics, Inc. |
| Location | Queensbury, NY |
| Product Type | Devices |
| Quantity | 80 boxes |
Product Description
ANGIODYNAMICS Percutaneous Introducer Set under the following labels: 1) 4 F Stiffened Micro-Introducer Kit, 45CM SS/T ECHO B PG, Item Number H787065970465, Catalog No.REF 06597046, 2) 4 F Stiffened Micro-Introducer Kit, 45CM SS/T ECHO S PG, Item Number H787065970485, Catalog No. REF 06597048 Indicated for percutaneous introduction of guidewire or catheter into the vascular system following a small 21-gauge needle stick
Reason for Recall
Greatbatch Medical the manufacturer of the 4F and 5F sheath/dilator components has determined that the products listed in their September 7, 2016 Recall Notification have the potential for the rotating luer to detach from the dilator hub during use. AngioDynamics has confirmed that affected sheath/dilators (Greatbatch Model Numbers 10904-001 and 10904-002) have been included in packaged AngioDynamics Stiffened Micro-Introducer Kits.
Distribution Pattern
Nationwide Distribution to AL, AR, CA, FL, GA, IL, KY, LA, MI, MN, MO, NC, OH, OK, SC, NY, ME, PA, MD, VA, WA, WI, WV, TN, and TX
Lot / Code Information
Batch/Lot: 1) 5074174, 2) 5043439, 5061389 & 5067424
Other Recalls from Angiodynamics, Inc.
| Recall # | Classification | Product | Date |
|---|---|---|---|
| Z-1391-2025 | Class II | IsoLoc Short Profile Prostate Immobilization Tr... | Feb 4, 2025 |
| Z-0770-2025 | Class II | AURYON LASER SYSTEM 100-120 VAC. Model Number: ... | Nov 25, 2024 |
| Z-2454-2024 | Class II | SOFT-VU KUMPE 5F X 65CM -Used for patients in n... | Jun 18, 2024 |
| Z-2453-2024 | Class II | SOFT-VU KUMPE 5F X 40CM -Used for patients in n... | Jun 18, 2024 |
| Z-2267-2024 | Class II | IsoLoc Prostate Immobilization Treatment Balloo... | May 21, 2024 |
Frequently Asked Questions
Contact your healthcare provider and the device manufacturer immediately. Check whether your specific model number and lot number are included in the recall scope. For external devices, stop using the affected product and arrange a replacement. For implanted devices, do not panic — removal is typically not required unless the risk assessment clearly indicates it. Your physician will guide you based on your individual clinical situation and the FDA's recommended actions. Report any adverse effects you may have experienced to FDA MedWatch at 1-800-FDA-1088.
Class I recalls indicate a reasonable probability of serious adverse health consequences or death from the defect. Class II recalls involve products that may cause temporary or medically reversible adverse health consequences, or where serious consequences are remote. Class III recalls cover products not likely to cause any adverse health consequences, typically involving technical regulatory violations. The classification guides urgency — Class I recalls require immediate action, while Class III may simply involve returning a product or acknowledging a labeling change. Always read the specific recall notice for recommended patient actions.
Report problems with medical devices to the FDA through MedWatch at 1-800-FDA-1088 or online at FDA.gov/safety/medwatch. Healthcare facilities are required by law to report device-related serious injuries and deaths. Patients and consumers can also report voluntarily. Include the device name, manufacturer, model number, and a description of the problem and any patient outcome. Reports from patients and clinicians help the FDA identify emerging safety signals and may trigger investigations that lead to recalls of dangerous devices.
What Should You Do?
Stop using this device if you are affected by this recall. Contact your healthcare provider and the manufacturer immediately for guidance. Report adverse events to FDA MedWatch.